Skip to main
NXTC
NXTC logo

Nextcure (NXTC) Stock Forecast & Price Target

Nextcure (NXTC) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 64%
Buy 18%
Hold 9%
Sell 9%
Strong Sell 0%

Bulls say

NextCure Inc. is poised for growth due to its promising product candidates, particularly LNCB74, which has shown superior efficacy in preclinical models compared to competitor constructs, suggesting a strong potential advantage in treating various cancers, including endometrial cancer. The preclinical results for NC181 indicate that it effectively targets ApoE4, showing robust efficacy in amyloid clearance and neuroinflammation, which is significant as it addresses Alzheimer’s disease, a major unmet medical need. Furthermore, the company's ongoing enrollment in clinical cohorts signals confidence in safety and effective development processes, enhancing its market positioning amidst a competitive landscape.

Bears say

NextCure Inc. is facing a negative outlook due to the discontinuation of Pfizer's B7-H4 ADC program, which raises concerns about the viability of B7-H4 targeted therapies like LNCB74. Additionally, the company's operating expenses in the fourth quarter of 2024 exceeded previous expectations, contributing to a revised price target. These factors reflect potential operational and market challenges that may hinder the company's growth and financial performance.

Nextcure (NXTC) has been analyzed by 11 analysts, with a consensus rating of Buy. 64% of analysts recommend a Strong Buy, 18% recommend Buy, 9% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nextcure (NXTC) Forecast

Analysts have given Nextcure (NXTC) a Buy based on their latest research and market trends.

According to 11 analysts, Nextcure (NXTC) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nextcure (NXTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.